Three companies made their Nasdaq debuts on Tuesday, and all three closed their first day of trading well above their offer prices. Iambic Therapeutics and City Therapeutics each rose more than 16%, while Exascale Labs surged 75% after announcing a roughly $8.2 million deal tied to Nvidia-powered servers.
The strong first-day showings are a reminder that the IPO market can still generate excitement, even as broader tech stocks have been volatile. The pops come at a time when investors are closely watching mega-cap tech moves and the direction of interest rates.
What's behind the pops?
An IPO pop—when a stock jumps on its first day of trading—is often driven by a mix of supply and demand. Right after a listing, the number of shares actually available to trade is often limited. The order book, which is the queue of buy and sell orders, can be thin. That means even a modest wave of buying can push the price up quickly.
This dynamic doesn't necessarily mean the companies are worth more than their IPO price. It reflects the mechanics of a new listing, where early trading can be volatile and prices can swing sharply in either direction.
For Iambic Therapeutics, a biotech company, and City Therapeutics, which is also in the biotech space, the double-digit gains suggest investors are willing to pay up for exposure to drug development. For Exascale Labs, the 75% jump was tied to a specific catalyst: an $8.2 million deal to supply servers powered by Nvidia's chips.
Why the Nvidia connection matters
Nvidia has become a bellwether for the artificial intelligence boom, and any company that announces a deal involving its hardware can attract attention. Exascale Labs' announcement of an $8.2 million order for Nvidia-powered servers is relatively small in the grand scheme of the AI infrastructure market, but it signals that the company is positioning itself in a hot area.
Investors have been pouring money into AI-related stocks, but they've also grown cautious about valuations and the sustainability of AI spending. The AI debt worries that have weighed on Nasdaq futures in recent weeks show that the enthusiasm is not without its skeptics.
What it means for everyday investors
For the average investor, IPO pops can be exciting, but they also come with risks. Buying a stock on its first day of trading means you're often paying a premium over the IPO price, and the early volatility can be intense. It's not uncommon for stocks to give back some of their first-day gains in the weeks that follow.
That doesn't mean IPOs are bad investments—many companies go on to perform well. But it's important to understand that the first-day pop is not the same as long-term value. It's a short-term trading event, driven by supply and demand, not necessarily by the company's fundamentals.
For those who missed the debut, there's no need to chase. IPOs are just one way to gain exposure to a company. You can also wait for the stock to settle and then decide if it fits your portfolio based on its business, financials, and growth prospects.
Broader market context
The Nasdaq has been under pressure recently, with chip stocks sliding and yields climbing. The Nasdaq's New Jersey outage that disrupted market data feeds earlier this month also added to the sense of uncertainty.
Still, the IPO market's ability to produce pops suggests there is appetite for new listings, especially in sectors tied to AI and biotech. Whether that appetite lasts will depend on the broader economy, interest rates, and corporate earnings.
For now, the three new listings have given investors something to cheer about. But as with any investment, it's wise to look beyond the first-day fireworks and focus on the underlying business.
